NURO has developed NUOS, the Neural Operating System. With NUOS, incapacitated patients with akinetic mutism from Trauma, Stroke and Neurodegenerative Diseases can communicate and compute instantly using neurological signals.
NUOS comes today in 2 commercially-ready editions, with 2 more in active development. It is fundamentally an architecture composed of hardware, software, algorithms and artificial intelligence.
Many clinicians in Ontario have told us that they do not have any tool like NUOS and that we are literally able to change the criteria of eligibility for patients with ZERO solution today.
We are Health Canada cleared, Northwestern University IRB cleared and US FDA cleared for some of the most advanced and critical conditions as the only non-invasive technology of its kind available today in the United States.
That said, we are now seeking as an Ontario-based company a review and a clearance from the MOHLTC ADP Program to sell NUOS across 27 ADP-approved hospitals and clinics in Ontario.
If any of you work with one of those ADP-approved institutions, we would love to speak with you to help achieve such goal before the May 2020 CEPP Equipment Pool review.
If you are able to assist, please communicate with me directly via email@example.com.
Thank you !!!
Francois Gand, HBSc.
NURO CORP. - Founder & CEO
Cohort Member of the Waterloo Accelerator Centre
Cohort Member of Communitech's Strategic Growth Team (MedTech)
Cohort Member of the Creative Destruction Lab (Artificial Intelligence)
Cohort Member of the INDIE BIO / SOSV Life Science Accelerator (San Francisco)
2018 Grand Prize Winner of the MIT Future of Healthcare Hacking and the MIT Barracuda Bowl
2019 Waterloo MedTech Top Start-Up Award Winner
Published by Fast Company, TechCrunch, Business Insider, Nanalyze and The Royal Society.